Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Transitional Cell 37Urinary Bladder Neoplasms 33Carcinoma, Renal Cell 30Carcinoma, Non-Small-Cell Lung 16Melanoma 15Prostatic Neoplasms 13Stomach Neoplasms 10Carcinoma, Hepatocellular 10Triple Negative Breast Neoplasms 9Kidney Neoplasms 9Colorectal Neoplasms 9Head and Neck Neoplasms 8Uterine Cervical Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Small Cell Lung Carcinoma 7Neoplasms 7Neoplasm Metastasis 6Lung Neoplasms 6Breast Neoplasms 6Ovarian Neoplasms 5Carcinoma, Merkel Cell 5Urologic Neoplasms 4Pancreatic Neoplasms 4Urethral Neoplasms 3Ureteral Neoplasms 3Esophageal Neoplasms 3Carcinoma, Squamous Cell 3Sarcoma 2Prostatic Neoplasms, Castration-Resistant 2Neuroendocrine Tumors 2

Interventions

atezolizumab 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1GSK 1363089 1Erlotinib Hydrochloride 1Disulfides 1Contrast Media 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Papillary renal cell carcinoma, sporadic × atezolizumab × Genitourinary × Clear all
NCT04981509 2026-06-03

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
65 enrolled
Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡